QUICK SEARCH:

[advanced]

	Author:		Keyword(s):

Home Help Feedback Subscriptions Archive Search Table of Contents

	Help viewing high resolution images
	Return to article

(Downloading may take up to 30 seconds.
If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.

Fig. 6. Knockout of PAF-receptor abrogates and treatment with the PAF-receptor antagonist ABT491 blunts PAF-induced stimulation of erythrocyte-annexin-binding. (A) Histograms of FITC-Annexin-V-binding as obtained by FACS analysis in a representative experiment of murine erythrocytes from a wild-type mouse (PAF-R^+/+; upper histograms) or a PAF receptor knockout mouse (PAF-R^–/–; lower histograms) incubated for 3 hours in Ringer solution containing DMSO vehicle (left histograms, control) or in Ringer solution containing 0.5 µM PAF16 (right histograms). Numbers give the percentage of annexin-positive cells. (B) FITC-Annexin-V-binding in % of control as obtained by FACS analysis of murine erythrocytes from PAF-R^+/+ (black bars) or PAF-R^–/– mice (white bars) after a 3-hour treatment with Ringer solution containing DMSO vehicle (0 µM), or after incubation with 0.5 µM PAF16 (arithmetic means ± s.e.m., n=10). * indicates significant difference from the respective control erythrocytes; # indicates significant difference from PAF-treated erythrocytes of PAF-R^+/+ mice (ANOVA, using Tukey's test as post-hoc test; P $≤$ 0.05). (C) FITC-Annexin-V-binding in % of control as obtained by FACS analysis of human erythrocytes (arithmetic means ± s.e.m., n=8), treated for 24 hours with Ringer solution containing DMSO vehicle (0 µM) or 0.5 µM PAF16 in the absence (black bars) or presence (white bars) of 1 µM ABT491. * indicates significant difference from the respective control erythrocytes; # indicates significant difference from PAF-treated erythrocytes in the absence of ABT491 (ANOVA, using Tukey's test as post-hoc test; P $≤$ 0.05).

Return to article